Dr. Massimo Crippa

1983 -1987

Graduate student,Weizmann Institute of Science, Rehovot, Israel.

1987

Ph.D. degree, Weizmann Institute of Science, Rehovot, Israel.

1988 - 1990

Visiting Fellow, National Cancer Institute, Bethesda (MD), U.S.A.

1990 - 1993

Visiting Associate, National Cancer Institute, Bethesda (MD), U.S.A.

April 1993

Senior Staff Fellow, Molecular Genetics, DIBIT - H.S.Raffaele Scientific Institute, Milan, Italy.

March 1999

Tutor, Universitā Vita e Salute, Medical School, Ospedale S. Raffaele, Milano, Italy.

• Landsman, D., McBride, O.W., Soares, N., Crippa, M.P., Srikantha, T. and Bustin, M. Chromosomal protein HMG-14: identification, characterization and chromosome localization of a functional gene from the large human multigene family. J. Biol. Chem. 264, 3421-3247. (1989).
• Crippa, M.P., Pash, J.M., Gerwin, B., Smithgall, T.E., Glazer, R.T. and Bustin, M. Expression of chromosomal proteins HMG-14 and HMG-17 in transformed human cells. Cancer Res. 50, 2022-2026. (1990).
• Bustin, M.,Crippa, M.P., and Pash, J. Immunochemical analysis of the exposure of HMG-14/-17 protein surfaces in chromatin. J. Biol. Chem., 265, 20077-20080. (1990).
• Crippa, M.P., Nickol, J.M. and Bustin, M. Differentiation dependent alterations in the chromatin structure of the chromosomal protein HMG-17 gene during erythropoiesis. J. Mol. Biol., 217: 75-84. (1991).
• Crippa, M.P., Nickol, J.M. and Bustin, M. Developmental changes in the expression of HMG chromosomal proteins during erythropoiesis. J. Biol. Chem. 266, 2712-2714. (1991).
• Bustin, M., Becerra, P. S.,Crippa, M.P., Lehn, D. S., Pash, J. M. and Shiloach, J. Recombinant human chromosomal proteins HMG-14 and HMG-17. - Nucl. Acids Res. 19, 3115-3121. (1991).
• Crippa, M.P., Alfonso, P.J. and Bustin, M. The nucleosome core binding region of chromosomal protein HMG-17 acts as an independent functional domain. J. Mol. Biol. 228, 442-449. (1992).
• Crippa, M.P., Trieschman, L., Alfonso, P.J., Wolffe, A.P. and Bustin, M. Deposition of HMG-17 during replication affects the transcriptional potential of polymerase III genes. E.M.B.O. J. 12, 3855- 3864 (1993).
• Alfonso, P.J., Crippa, M.P., Hayes, J.J. and Bustin, M. The footprint of chromosomal proteins HMG-14 and HMG-17 on chromatin subunits. J. Mol. Biol. 236, 189-198 (1993).
• Trieschmann, L., Alfonso, P.J., Crippa, M.P., Wolffe, A.P. and Bustin, M. Incorporation of chromosomal proteins HMG-14/-17 into nascent nucleosomes induces an extended chromatin conformation and enhances the utilization of active transcription complexes. E.M.B.O. J. 14, 1478-1489 (1995).
• Riittinen, L., Limongi, P., Crippa, M.P., Conese, M., Hernandez-Marrero, L.; Fazioli, F. and Blasi, F. Removal of domain D2 or D3 of the human urokinase receptor does not affect ligand activity. F.E.B.S. Letters 381, 1-6 (1996).
• Ibaņez-Tallon, I., Caretti, G., Blasi, F. and Crippa, M.P., In vivo" analysis of the state of the human uPA enhancer following stimulation by TPA. Oncogene. Oncogene 18, 2836-2845. (1999).
• Miralles, F.; Ibaņez-Tallon, I.; Parra, M.; Crippa, M.P.; Blasi, F.; Besser, D.; Nagamine, Y. and Muņoz-Canoves, P. Transcriptional regulation of the murine urokinase-type plasminogen activator gene in skeletal myoblasts. Thrombosis and Heamostasis 81, 767-774. (1999).
• Suzuki, Y.; Shudo, K.; Matsumure, Crippa, M.P., and Kojima, S. Physical interaction between retinoic acid receptor and SP1 mediates induction of urokinase by retinoic acid. Blood 93, 4264-4276. (1999).
• Hayashi, S.; Suzuki, Y.; Crippa, M.P.,; Friedman, S.L. and Kojima, S. Zf9, a novel transcriptional regulator of urokinase-type plasminogen activator in endothelial cells. Implications for vascular injury. (1999). (in press).